医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LFB S.A.宣布,评估重组因子7有效性的PerSept 1前瞻性临床试验达到患者入组目标

2014年12月18日 PM11:26
このエントリーをはてなブックマークに追加
Related Posts Plugin for WordPress, Blogger...
TimeLine:

同じカテゴリーの記事 

  • Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen
  • InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China
  • Disclosure of data on Agaricus blazei mushroom, KA21′s immunity-enhancing mechanism, immunological enhancement effect confirmed by human clinical trials, and candida and other types of fungal infection, Toei Shinyaku
  • Disclosure of data on effects of Agaricus blazei mushroom, KA21 strain for improvement of hair loss & gray hair in human clinical trials and promotion of hair growth in mice, Toei Shinyaku
  • Survey of degree of satisfaction with Agaricus blazei mushroom KA21 for promoting the health of senior dogs and cats among veterinarians and pet owners, Toei Shinyaku